Cardiovascular and Renal Pharmacology Lecture Notes

Comprehensive vocabulary flashcards covering cardiovascular and renal pharmacology including diuretics, beta blockers, RAAS inhibitors, calcium channel blockers, digoxin, statins, and antianginals.

Thiazide Diuretics: Primary Nephron Site and Mechanism

Inhibits the reabsorption of sodium, potassium, chloride, and water into the bloodstream at the end of the ascending loop of Henle.

Thiazide Diuretics: Long-Term Vascular Mechanism

Dilates the smooth muscle of arterioles, reducing peripheral vascular resistance so the heart does not work as hard to pump blood.

Thiazide Diuretics: Representative Drug Examples

Chlorothiazide and hydrochlorothiazide.

Thiazide Diuretics: Daily Weight Protocol

Weigh the patient daily at consistent times to monitor fluid loss trends and prevent dehydration.

Thiazide Diuretics: Side Effects of Sodium and Water Loss

Headache and dizziness resulting from intravascular volume depletion and hyponatremia.

Thiazide Diuretics: Hypokalemia Signs and Dietary Replacement

Presents with muscle cramps, twitching, irregular heart rate, anorexia, nausea, and vomiting; managed by consuming bananas, citrus fruits, and leafy greens.

Thiazide Diuretics: Diabetic Patient Monitoring

Carefully track blood glucose levels because thiazide therapy can alter glycemic control in diabetic individuals.

Loop Diuretics: Anatomical Site and Class Potency

Blocks active transport of chloride, sodium, water, and potassium in the thick ascending loop of Henle; considered the most powerful diuretic class.

Loop Diuretics: Representative Drug Examples

Furosemide and bumetanide.

Loop Diuretics: Primary Clinical Indications

Severe fluid retention conditions including heart failure, pulmonary edema, and cirrhosis of the liver when the body is filled with fluid.

Loop Diuretics: Signs of Potassium Depletion

Dry mouth, increased thirst, muscle cramps, fatigue, generalized weakness, and mood alterations.

Loop Diuretics: Ototoxicity Adverse Effect

A critical auditory complication presenting with decreased hearing or ringing in the ears (tinnitus) that must be reported immediately.

Loop Diuretics: Patient Safety and Fluid Monitoring

Teach slow position changes to mitigate orthostatic hypotension, monitor diabetic blood glucose, and record accurate intake and urine output.

Spironolactone: Site and Mechanism of Action

Acts on the distal tubule and collecting ducts of the nephron to slow the sodium pump, excreting sodium and water while retaining potassium.

Spironolactone: Renal Function Lab Monitoring

Assess blood urea nitrogen (BUN) and serum creatinine levels to evaluate baseline and ongoing kidney function.

Spironolactone: Critical Cardiac Glycoside Interaction

Concurrent administration with digoxin elevates the risk of developing fatal cardiac dysrhythmias.

Hyperkalemia: Laboratory Threshold and Clinical Presentation

Serum potassium concentration rising above the normal range of $3.5\text{--}5$; manifests as confusion, irregular heart rhythm, nervousness, numbness or tingling in the hands and feet, unusual fatigue, and heavy legs.

Potassium-Sparing Diuretics: Dietary and Ambulation Guidance

Instruct the patient to avoid potassium-rich foods and potassium supplements, and advise rising slowly from sitting or lying positions.

Non-Selective Beta-Adrenergic Blockers: Receptors and Cardiovascular Effect

Blocks both beta-$1$ receptors (decreasing myocardial contractility and heart rate) and beta-$2$ receptors (causing bronchoconstriction); identified by the suffix -olol.

Non-Selective Beta-Adrenergic Blockers: Respiratory Contraindications

Contraindicated in asthma, chronic obstructive pulmonary disease (COPD), and emphysema due to the risk of bronchospasm.

Propranolol: Receptor Classification

A non-selective beta-adrenergic blocker that antagonizes both beta-$1$ cardiac and beta-$2$ bronchial receptors.

Selective Beta-Adrenergic Blockers: Receptor Target and Examples

Cardioselective agents (such as atenolol and metoprolol) that selectively target beta-$1$ adrenergic receptors.

Beta-Adrenergic Blockers: Vital Sign Withholding Parameters

Withhold the dose and alert the healthcare provider if the patient heart rate is below $60$ or systolic blood pressure is below $90$.

Beta-Adrenergic Blockers: Hypoglycemia Masking and Cessation Precaution

Can conceal sympathetic tachycardia symptoms of hypoglycemia in diabetic patients; must never be stopped abruptly to prevent rebound hypertension.

Beta-Adrenergic Blockers: Common Patient-Reported Side Effects

Decreased sexual ability, dizziness, drowsiness, insomnia, weakness, cold hands and feet, and signs of depression.

Combined Alpha and Beta Blockers: Dual Mechanism

Dilates blood vessels via alpha-$1$ blockade while simultaneously decreasing heart rate and myocardial contractility via beta-$1$ blockade.

Labetalol: First-Dose Patient Precaution

Instruct the patient to avoid operating heavy machinery or driving for $24\text{ hours}$ following the initial dose due to profound blood pressure drops.

Labetalol: Weight Monitoring and Side Effects

Instruct patients to weigh themselves twice weekly to monitor for fluid retention, and assess for dizziness, stuffy nose, and fatigue.

Renin-Angiotensin-Aldosterone System (RAAS) Drugs: Overall Hemodynamic Effect

Lowers systemic blood pressure through the combined reduction of peripheral vasoconstriction and circulatory fluid volume.

Angiotensin-Converting Enzyme (ACE) Inhibitors: Mechanism and Suffix

Medications ending in -pril that lower blood pressure by blocking the conversion of angiotensin $1$ to angiotensin $2$.

ACE Inhibitors: Characteristic Upper Respiratory Side Effect

A persistent, dry, hacking cough and throat tickle resulting from bradykinin accumulation.

Angiotensin II Receptor Blockers (ARBs): Mechanism and Suffix

Medications ending in -sartan that block angiotensin $2$ from binding to receptors, preventing vasoconstriction and aldosterone secretion.

RAAS Inhibitors: Angioedema Manifestation

A severe hypersensitivity emergency characterized by rapid swelling of the eyes, mouth, face, and tongue.

RAAS Inhibitors: Pregnancy and Lifestyle Contraindications

Strictly contraindicated during pregnancy due to the risk of severe fetal injury and birth defects; alcohol consumption must be avoided.

RAAS Inhibitors: First-Dose Precautions and Electrolyte Risk

Monitor for profound first-dose hypotension and dizziness leading to fall risk; monitor potassium levels due to the risk of hyperkalemia.

Calcium Channel Blockers: Primary Mechanism and Drug Classes

Promote arterial vasodilation to lower blood pressure; includes verapamil and dihydropyridine agents ending in -dipine (such as amlodipine).

Calcium Channel Blockers: Dietary and Clinical Contraindications

Avoided in patients with heart failure, contraindicated with grapefruit juice, and avoided with alcohol due to severe hypotensive risk.

Calcium Channel Blockers: Stevens-Johnson Syndrome

A serious systemic adverse reaction presenting with widespread skin lesions, fever, and severe aching joints.

Calcium Channel Blockers: Administration Timing and Edema Monitoring

Must be taken at the same time every day, positions changed slowly, and legs inspected for peripheral edema caused by fluid retention.

Verapamil: Distinct Physiological Effects

Increases coronary blood flow directly to the myocardium while frequently causing severe constipation.

Digoxin: Pharmacologic Class and Inotropic Action

A cardiac glycoside that functions as a positive inotrope, activating contractile proteins in cardiac muscle to augment contractile force.

Digoxin: Primary Clinical Indication

Indicated for symptom management in patients diagnosed with advanced heart failure.

Digoxin: Therapeutic and Optimal Blood Ranges

The standard therapeutic serum window is $0.5\text{--}2\text{ ng/mL}$, while the target optimal blood level is $0.5\text{--}0.8\text{ ng/mL}$.

Digoxin Toxicity: Gastrointestinal and Neuropsychiatric Manifestations

Presents early with anorexia, nausea, vomiting, and diarrhea, accompanied by confusion, anxiety, and depression.

Digoxin Toxicity: Visual and Rhythm Disturbances

Characteristic blurred or yellow-tinted vision and potentially lethal irregular heart rhythms (dysrhythmias).

Digoxin: Pulse Assessment and Withholding Criteria

Auscultate the apical pulse for one full minute and withhold the dose if the pulse rate is below $60$.

Digoxin: Dosing Schedule and Missed Dose Window

Must be taken at the same time each day; the patient has a $12\text{ hours}$ window to take a missed dose.

Digoxin: Key Pharmacologic Drug Interactions

Interacts adversely with beta blockers, calcium gluconate, calcium chloride, succinylcholine, and verapamil.

Statins (HMG-CoA Reductase Inhibitors): Mechanism and Primary Target

Reduces circulating blood LDL levels by inhibiting the rate-limiting hepatic enzyme responsible for cholesterol synthesis.

Statins: Critical Musculoskeletal Adverse Reaction

Rhabdomyolysis (skeletal muscle breakdown), signaled by severe muscle pain, dark tea-colored urine, and decreased urine output.

Statins: Manifestations of Liver Dysfunction

Nausea, jaundice (yellowing of skin/eyes), dark urine, light clay-colored stools, and persistent gastrointestinal upset.

Statins: Contraindications and Substance Interactions

Strictly contraindicated in pregnancy; interacts negatively with grapefruit juice, alcohol, acetaminophen, aspirin, and antacids.

Statins: Laboratory Monitoring Protocol

Blood lipid panels are drawn in the morning, evaluated initially at $3\text{ to }6\text{ months}$, and monitored annually thereafter.

Nitroglycerin: Primary Indication and Expected Side Effect

Administered to relieve angina (chest pain); commonly causes an intense, throbbing headache due to rapid cranial vasodilation.

Nitroglycerin: Sublingual Administration Protocol

Place $1$ tablet under the tongue at the immediate onset of chest pain, repeating every $5\text{ minutes}$ up to a maximum of $3$ doses.

Nitroglycerin: Serious Hemodynamic Adverse Reactions

Orthostatic hypotension, reflex tachycardia, paradoxical bradycardia, vertigo, and severe generalized weakness.

Nitroglycerin: Healthcare Provider Handling Precaution

Nurses must wear gloves when handling and applying the drug to prevent cutaneous absorption, severe headache, and hypotension.

Thiazide Diuretics: Primary Nephron Site and Mechanism

Inhibits the reabsorption of sodium, potassium, chloride, and water into the bloodstream at the end of the ascending loop of Henle.

Thiazide Diuretics: Long-Term Vascular Mechanism

Dilates the smooth muscle of arterioles, reducing peripheral vascular resistance so the heart does not work as hard to pump blood.

Thiazide Diuretics: Representative Drug Examples

Chlorothiazide and hydrochlorothiazide (HCTZ).

Thiazide Diuretics: Daily Weight Protocol

Weigh the patient daily at consistent times to monitor fluid loss trends and prevent dehydration.

Thiazide Diuretics: Side Effects of Sodium and Water Loss

Headache and dizziness resulting from intravascular volume depletion and hyponatremia.

Thiazide Diuretics: Hypokalemia Signs and Dietary Replacement

Presents with muscle cramps, twitching, irregular heart rate, anorexia, nausea, and vomiting; managed by consuming bananas, citrus fruits, and leafy greens.

Thiazide Diuretics: Diabetic Patient Monitoring

Carefully track blood glucose levels because thiazide therapy can alter glycemic control and cause hyperglycemia in diabetic individuals.

Loop Diuretics: Anatomical Site and Class Potency

Blocks active transport of chloride, sodium, water, and potassium in the thick ascending loop of Henle; considered the most powerful diuretic class.

Loop Diuretics: Representative Drug Examples

Furosemide (Lasix) and bumetanide (Bumex).

Loop Diuretics: Primary Clinical Indications

Severe fluid retention conditions including heart failure, pulmonary edema, and cirrhosis of the liver when the body is filled with fluid.

Loop Diuretics: Signs of Potassium Depletion

Dry mouth, increased thirst, muscle cramps, fatigue, generalized weakness, and mood alterations.

Loop Diuretics: Ototoxicity Adverse Effect

A critical auditory complication presenting with decreased hearing or ringing in the ears (tinnitus) that must be reported immediately.

Loop Diuretics: Patient Safety and Fluid Monitoring

Teach slow position changes to mitigate orthostatic hypotension, monitor diabetic blood glucose, and record accurate intake and urine output.

Spironolactone: Site and Mechanism of Action

Acts on the distal tubule and collecting ducts of the nephron to slow the sodium pump, excreting sodium and water while retaining potassium.

Spironolactone: Renal Function Lab Monitoring

Assess blood urea nitrogen (BUN) and serum creatinine levels to evaluate baseline and ongoing kidney function.

Spironolactone: Critical Cardiac Glycoside Interaction

Concurrent administration with digoxin elevates the risk of developing fatal cardiac dysrhythmias.

Hyperkalemia: Laboratory Threshold and Clinical Presentation

Serum potassium concentration rising above the normal range of $3.5\text{--}5.0\,\text{mEq/L}$; manifests as confusion, irregular heart rhythm, nervousness, numbness or tingling in the hands and feet, unusual fatigue, and heavy legs.

Potassium-Sparing Diuretics: Dietary and Ambulation Guidance

Instruct the patient to avoid potassium-rich foods, salt substitutes containing potassium, and potassium supplements, and advise rising slowly from sitting or lying positions.

Non-Selective Beta-Adrenergic Blockers: Receptors and Cardiovascular Effect

Blocks both beta-$1$ receptors (decreasing myocardial contractility and heart rate) and beta-$2$ receptors (causing bronchoconstriction); identified by the suffix -olol.

Non-Selective Beta-Adrenergic Blockers: Respiratory Contraindications

Contraindicated in asthma, chronic obstructive pulmonary disease (COPD), and emphysema due to the risk of bronchospasm.

Propranolol: Receptor Classification

A non-selective beta-adrenergic blocker that antagonizes both beta-$1$ cardiac and beta-$2$ bronchial receptors.

Selective Beta-Adrenergic Blockers: Receptor Target and Examples

Cardioselective agents (such as atenolol and metoprolol) that selectively target beta-$1$ adrenergic receptors.

Beta-Adrenergic Blockers: Vital Sign Withholding Parameters

Withhold the dose and alert the healthcare provider if the patient heart rate is below $60\,\text{bpm}$ or systolic blood pressure is below $90\,\text{mmHg}$.

Beta-Adrenergic Blockers: Hypoglycemia Masking and Cessation Precaution

Can conceal sympathetic tachycardia symptoms of hypoglycemia in diabetic patients; must never be stopped abruptly to prevent rebound hypertension.

Beta-Adrenergic Blockers: Common Patient-Reported Side Effects

Decreased sexual ability, dizziness, drowsiness, insomnia, weakness, cold hands and feet, and signs of depression.

Combined Alpha and Beta Blockers: Dual Mechanism

Dilates blood vessels via alpha-$1$ blockade while simultaneously decreasing heart rate and myocardial contractility via beta-$1$ blockade.

Labetalol: First-Dose Patient Precaution

Instruct the patient to avoid operating heavy machinery or driving for $24\,\text{hours}$ following the initial dose due to profound blood pressure drops.

Labetalol: Weight Monitoring and Side Effects

Instruct patients to weigh themselves twice weekly to monitor for fluid retention, and assess for dizziness, stuffy nose, and fatigue.

Renin-Angiotensin-Aldosterone System (RAAS) Drugs: Overall Hemodynamic Effect

Lowers systemic blood pressure through the combined reduction of peripheral vasoconstriction and circulatory fluid volume.

Angiotensin-Converting Enzyme (ACE) Inhibitors: Mechanism and Suffix

Medications ending in -pril that lower blood pressure by blocking the conversion of angiotensin $1$ to angiotensin $2$.

ACE Inhibitors: Characteristic Upper Respiratory Side Effect

A persistent, dry, hacking cough and throat tickle resulting from bradykinin accumulation.

Angiotensin II Receptor Blockers (ARBs): Mechanism and Suffix

Medications ending in -sartan that block angiotensin $2$ from binding to receptors, preventing vasoconstriction and aldosterone secretion.

RAAS Inhibitors: Angioedema Manifestation

A severe hypersensitivity emergency characterized by rapid swelling of the eyes, mouth, face, and tongue.

RAAS Inhibitors: Pregnancy and Lifestyle Contraindications

Strictly contraindicated during pregnancy due to the risk of severe fetal injury and birth defects; alcohol consumption must be avoided.

RAAS Inhibitors: First-Dose Precautions and Electrolyte Risk

Monitor for profound first-dose hypotension and dizziness leading to fall risk; monitor potassium levels due to the risk of hyperkalemia.

Calcium Channel Blockers: Primary Mechanism and Drug Classes

Promote arterial vasodilation to lower blood pressure; includes verapamil and dihydropyridine agents ending in -dipine (such as amlodipine).

Calcium Channel Blockers: Dietary and Clinical Contraindications

Avoided in patients with heart failure, contraindicated with grapefruit juice, and avoided with alcohol due to severe hypotensive risk.

Calcium Channel Blockers: Stevens-Johnson Syndrome

A serious systemic adverse reaction presenting with widespread skin lesions, fever, and severe aching joints.

Calcium Channel Blockers: Administration Timing and Edema Monitoring

Must be taken at the same time every day, positions changed slowly, and legs inspected for peripheral edema caused by fluid retention.

Verapamil: Distinct Physiological Effects

Increases coronary blood flow directly to the myocardium while frequently causing severe constipation and bradycardia.

Digoxin: Pharmacologic Class and Inotropic Action

A cardiac glycoside that functions as a positive inotrope, activating contractile proteins in cardiac muscle to augment contractile force.

Digoxin: Primary Clinical Indication

Indicated for symptom management in patients diagnosed with advanced heart failure.

Digoxin: Therapeutic and Optimal Blood Ranges

The standard therapeutic serum window is $0.5\text{--}2.0\,\text{ng/mL}$, while the target optimal blood level for heart failure is $0.5\text{--}0.8\,\text{ng/mL}$ or $0.5\text{--}0.9\,\text{ng/mL}$.